Outcomes after prostate brachytherapy are even better than predicted

During the first 3 years after prostate cancer treatment with radiation therapy, benign prostate‐specific antigen (PSA) bounces are difficult for clinicians to distinguish from a biochemical recurrence, which can result in unnecessary interventions and erroneous predictions of outcomes. The objective of this study was to evaluate a commonly used PSA failure definition in a multinational, multi‐institutional study after monotherapy with prostate brachytherapy.

[1]  E. Steyerberg,et al.  [Regression modeling strategies]. , 2011, Revista espanola de cardiologia.

[2]  K. Nakagawa,et al.  Prediction of PSA bounce after permanent prostate brachytherapy for localized prostate cancer , 2009, International Journal of Clinical Oncology.

[3]  A. Vickers,et al.  Low annual caseloads of United States surgeons conducting radical prostatectomy. , 2009, The Journal of urology.

[4]  J. Ciezki,et al.  Prostate-specific antigen bounce after prostate brachytherapy: review of a confusing phenomenon. , 2009, Urology.

[5]  D. Kuban,et al.  Prostogram predicted brachytherapy outcomes are not universally accurate: an analysis based on the M. D. Anderson Cancer Center experience with (125)iodine brachytherapy. , 2009, The Journal of urology.

[6]  S. Kanazawa,et al.  Prostate‐specific antigen ‘bounce’ after permanent 125I‐implant brachytherapy in Japanese men: a multi‐institutional pooled analysis , 2009, BJU international.

[7]  Wadih Arap,et al.  Quality of life and satisfaction with outcome among prostate-cancer survivors. , 2008, The New England journal of medicine.

[8]  J. Logue,et al.  Analysis of prostate-specific antigen bounce after I(125) permanent seed implant for localised prostate cancer. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  G. Lockwood,et al.  PSA kinetics and PSA bounce following permanent seed prostate brachytherapy. , 2007, International journal of radiation oncology, biology, physics.

[10]  Steven J Frank,et al.  An assessment of quality of life following radical prostatectomy, high dose external beam radiation therapy and brachytherapy iodine implantation as monotherapies for localized prostate cancer. , 2007, The Journal of urology.

[11]  M. Zelefsky.  PSA bounce versus biochemical failure following prostate brachytherapy , 2006, Nature Clinical Practice Urology.

[12]  A. K. Levinson,et al.  Prostate specific antigen bounce after simultaneous irradiation for prostate cancer: the relationship to patient age. , 2003, The Journal of urology.

[13]  R. Stock,et al.  Prostate-specific antigen bounce after prostate seed implantation for localized prostate cancer: descriptions and implications. , 2003, International journal of radiation oncology, biology, physics.

[14]  A. Renshaw,et al.  Using the magnitude of PSA bounce after MRI-guided prostate brachytherapy to distinguish recurrence, benign precipitating factors, and idiopathic bounce. , 2002, International journal of radiation oncology, biology, physics.

[15]  K. Wallner,et al.  Prostate-specific antigen spikes after permanent prostate brachytherapy. , 2002, International journal of radiation oncology, biology, physics.

[16]  J. Blasko,et al.  Pretreatment nomogram for predicting freedom from recurrence after permanent prostate brachytherapy in prostate cancer. , 2001, Urology.

[17]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[18]  J. Blasko,et al.  Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. , 2000, Seminars in urologic oncology.

[19]  A. K. Levinson,et al.  Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer. , 2000, Journal of Urology.

[20]  R. Stock,et al.  A dose-response study for I-125 prostate implants. , 1998, International journal of radiation oncology, biology, physics.

[21]  D. Brizel,et al.  National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology , 2012 .

[22]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[23]  J. Millar,et al.  Prostate-specific antigen bounce after permanent iodine-125 prostate brachytherapy--an Australian analysis. , 2011, International journal of radiation oncology, biology, physics.